Abstract
The involvement of the glutamate-glycine activated ion channels of the NMDA receptor in various neurophysiological processes has made this ion channel the focus of intense research. The excessive release of glutamate in a variety of neuronal hypoxic conditions implicates the NMDA receptor in a number of neuropatholological states, such as stroke, chronic pain, Parkinsons disease, Alzheimers disease, ALS, and epilepsy, among others, thus making this receptor a prime drug target candidate. A variety of agents are known to be effective in opening and closing of the ion channels of this receptor, among the latter group of agents is the peptidic conantokins. Through the use of electrophysiological measurements with a number of cell types containing natural and recombinant subunits of the NMDA receptor, much knowledge is evolving regarding the mechanism of action of activators and inhibitors of the NMDA receptor ion channels. In addition, structure-function studies of the conantokins in these systems have been revealing in terms of their complimentary sites on the NMDA receptor. These relationships serve as the main focus of this review.
Keywords: NMDA Receptor, electrophysiological measurements, C-terminal residues, GLA RESIDUES IN CONANTOKIN, NR1b NR2B, hippocampal neurons
Current Drug Targets
Title: Activators and Inhibitors of the Ion Channel of the NMDA Receptor
Volume: 2 Issue: 3
Author(s): Rebecca C. Klein and Francis J. Castellino
Affiliation:
Keywords: NMDA Receptor, electrophysiological measurements, C-terminal residues, GLA RESIDUES IN CONANTOKIN, NR1b NR2B, hippocampal neurons
Abstract: The involvement of the glutamate-glycine activated ion channels of the NMDA receptor in various neurophysiological processes has made this ion channel the focus of intense research. The excessive release of glutamate in a variety of neuronal hypoxic conditions implicates the NMDA receptor in a number of neuropatholological states, such as stroke, chronic pain, Parkinsons disease, Alzheimers disease, ALS, and epilepsy, among others, thus making this receptor a prime drug target candidate. A variety of agents are known to be effective in opening and closing of the ion channels of this receptor, among the latter group of agents is the peptidic conantokins. Through the use of electrophysiological measurements with a number of cell types containing natural and recombinant subunits of the NMDA receptor, much knowledge is evolving regarding the mechanism of action of activators and inhibitors of the NMDA receptor ion channels. In addition, structure-function studies of the conantokins in these systems have been revealing in terms of their complimentary sites on the NMDA receptor. These relationships serve as the main focus of this review.
Export Options
About this article
Cite this article as:
Klein C. Rebecca and Castellino J. Francis, Activators and Inhibitors of the Ion Channel of the NMDA Receptor, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348290
DOI https://dx.doi.org/10.2174/1389450013348290 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intracranial Cerebrospinal Fluid Volume Evaluation in Healthy People and Hydrocephalus Patients using SPACE Sequence
Current Medical Imaging Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease
Current Alzheimer Research Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Inflammatory Mediators in Epilepsy
Current Pharmaceutical Design Subject Index To Volume 12
Current Pharmaceutical Design VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Seeing Early Signs of Alzheimer's Disease Through the Lens of the Eye
Current Alzheimer Research The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option
Current Neuropharmacology Application of Pharmacophore Models for the Design and Synthesis of New Anticonvulsant Drugs
Mini-Reviews in Medicinal Chemistry Drug Repositioning: Antimalarial Activities of GABA Analogs in Mice Infected with <i>Plasmodium berghei</i>
Central Nervous System Agents in Medicinal Chemistry The Infectious Etiology of Alzheimer’s Disease
Current Neuropharmacology MG17, A Novel Triazole Derivative Abrogated Neuroinflammation and Related Neurodegenerative Symptoms in Rodents
Current Molecular Pharmacology Gut Microbiota as a Link between Modern Lifestyle and Alzheimer’s Disease
Current Aging Science PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo
Current Drug Metabolism Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Anticonvulsant Activity of New GABA Prodrugs
Medicinal Chemistry Mechanisms Underlying Anti-hyperalgesic Properties of Kaempferol-3,7- di-O-α-L-rhamnopyranoside Isolated from Dryopteris cycadina
Current Topics in Medicinal Chemistry Epigenetics in Vascular Disease – Therapeutic Potential of New Agents
Current Vascular Pharmacology